Product image of Hatteras (Atorvastatin, Ezetimibe) supplied by GNH India

Hatteras

Active Ingredient:
Atorvastatin, Ezetimibe
Origin:
EU

Hatteras (Atorvastatin, Ezetimibe)

Hatteras is a prescription oral medication that combines the statin atorvastatin with the cholesterol absorption inhibitor ezetimibe. The fixed‑dose combination is formulated for the treatment of elevated cholesterol and mixed dyslipidemia in adults. It belongs to the statin and cholesterol absorption inhibitor class and is marketed in the European Union. The product is taken by mouth and requires a health‑care provider’s prescription in accordance with local clinical guidelines.

Manufacturer / TM Owner

I.B.N. Savio S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Hatteras is indicated for the management of several lipid disorders in adult patients.

  • Primary hypercholesterolemia (elevated LDL‑C).
  • Mixed dyslipidemia (elevated LDL‑C and triglycerides).
  • Familial hypercholesterolemia when diet and lifestyle alone are insufficient.
  • Patients who require additional LDL‑C reduction beyond statin monotherapy.
  • Adjunct therapy after myocardial infarction or stroke to lower cardiovascular risk, if prescribed.

Side Effects

The safety profile of Hatteras reflects the combined effects of atorvastatin and ezetimibe, with most patients experiencing mild, transient events.

Common

  • Muscle aches or weakness.
  • Headache.
  • Diarrhea or abdominal discomfort.
  • Elevated liver enzymes (transient).
  • Nausea or loss of appetite.

Serious

  • Rhabdomyolysis or severe muscle breakdown.
  • Acute liver injury or hepatitis.
  • Persistent elevation of creatine kinase.
  • Severe allergic reaction (angioedema, anaphylaxis).

Precautions & Warnings

Before initiating Hatteras, clinicians should evaluate patient history and laboratory values to minimize risks.

  • Assess baseline liver function tests; avoid use in active liver disease.
  • Review muscle‑related conditions and avoid in patients with unexplained muscle pain.
  • Use caution in pregnant or breastfeeding women; safety not established.
  • Adjust dose in patients with severe renal impairment.
  • Monitor lipid profile and liver enzymes periodically during therapy.
  • Consider drug interactions with strong CYP3A4 inhibitors.

Avoid Interactions

Hatteras may interact with other medicines that affect its metabolism or increase the risk of muscle toxicity.

Avoid

  • Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole).
  • Fibrates (gemfibrozil) due to heightened rhabdomyolysis risk.
  • Cyclosporine or tacrolimus, which raise statin concentrations.

Use with caution

  • Other lipid‑lowering agents (niacin, omega‑3 fatty acids).
  • Anticoagulants (warfarin) because of possible INR changes.
  • Antacids containing aluminum or magnesium may reduce ezetimibe absorption.

Frequently Asked Questions

Hatteras combines atorvastatin, which inhibits HMG‑CoA reductase to lower hepatic cholesterol synthesis, with ezetimibe, which blocks the NPC1L1 transporter to reduce intestinal cholesterol absorption.

Hatteras is prescribed for primary hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia when diet and lifestyle measures are insufficient.

Hatteras is taken orally, usually once daily, with or without food as directed by a health‑care professional.

Safety of Hatteras in pregnancy has not been established; it should be used only if the potential benefit justifies the potential risk to the fetus.

Baseline and periodic monitoring of liver function tests, creatine kinase, and lipid panels are recommended during treatment with Hatteras.

Common side effects include muscle aches, headache, diarrhea, transient elevation of liver enzymes, and nausea.

Serious reactions such as rhabdomyolysis, severe liver injury, marked elevation of creatine kinase, or signs of an allergic reaction (e.g., swelling, difficulty breathing) should prompt urgent medical evaluation.

Co‑administration with other lipid‑lowering agents can be done, but caution is advised, especially with fibrates or high‑dose niacin, due to increased risk of muscle toxicity.

Patients with severe renal impairment may require dose adjustment and closer monitoring because reduced clearance can increase drug exposure.

Moderate alcohol intake is generally permissible, but excessive consumption can worsen liver function and should be avoided.

Certain supplements, such as high‑dose green tea extract or St. John’s wort, may affect statin metabolism and should be discussed with a health‑care provider.

If a dose is missed, take it as soon as remembered unless it is near the time of the next scheduled dose; do not double the dose.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Atorvastatin, Ezetimibe

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT